Shingrix Uptake May Be Slowed By Part D Cost Sharing With Chart: Current Market Access to Shingrix

Since GlaxoSmithKline plc’s Shingrix (zoster vaccine recombinant, adjuvanted) launched in early 2018, a steady number of adults ages 50 and older have been getting the shingles vaccine. But a confusing patchwork of adult vaccine coverage — one that leads to significant out-of-pocket expenses for many in the vaccine’s target population — may be leaving some patients behind, analysts say.

Richard Hughes IV, managing director at Avalere Health, tells AIS Health that commercial plan members can receive Shingrix with no cost sharing, but Medicare Part D members generally face cost sharing of around $50 or more. Some Medicaid plans don’t cover the vaccine at all, he adds. The two-shot Shingrix series costs around $280 without insurance.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today